Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ziltivekimab - Novo Nordisk

Next Previous
Drug Profile

Ziltivekimab - Novo Nordisk

Alternative Names: COR 001; EX-6018; MEDI-5117; NN-6018; WBP-216

Latest Information Update: 10 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer MedImmune; Novo Nordisk
  • Class Anti-inflammatories; Anti-ischaemics; Antirheumatics; Cardiovascular therapies; Heart failure therapies; Monoclonal antibodies
  • Mechanism of Action Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders; Heart failure; Myocardial infarction
  • No development reported Kidney disorders
  • Discontinued Autoimmune disorders; Rheumatoid arthritis

Most Recent Events

  • 31 Jul 2026 Efficacy and adverse evenet data from a phase III trial in Cardiovascular disorders released by Novo Nordis
  • 09 Jun 2026 Novo Nordisk completes a phase III trial in Cardiovascular disorders in US, Canada, Denmark, Greece, Japan, Lithuania, Slovakia, Sweden, Argentina, Australia, Belgium, Brazil, Bulgaria, China, Croatia, Germany, Hungary, India, Italy, South Korea, Malaysia, Mexico, Netherlands, Poland, Romania, Russia, Serbia, Spain, South Africa, Taiwan, Thailand, Turkey, the UK, Ukraine, Czech Republic, Portugal, Latvia, and Israel (NCT05021835)
  • 19 Dec 2025 Phase-III clinical trials in Myocardial infarction in Switzerland (SC) (NCT07276282)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top